The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Open accessAbstract
Glucagon-like peptide 1 (GLP-1) is a hormone secreted predominantly by the distal small intestine and colon and released in response to enteral nutrient exposure. GLP-1-based therapies are now used widely in the management of type 2 diabetes and have the potential to be effective antiobesity agents. Although widely known as an incretin hormone, there is a growing body of evidence that GLP-1 also acts as an enterogastrone, with profound effects on the gastrointestinal motor system. Moreover, the effects of GLP-1 on gastrointestinal motility appear to be pivotal to its effect of reducing postprandial glycaemic excursions and may, potentially, represent the dominant mechanism. This review summarizes current knowledge of the enterogastrone properties of GLP-1, focusing on its effects on gut motility at physiological and pharmacological concentrations, and the motor actions of incretin-based therapies. While of potential importance, the inhibitory action of GLP-1 on gastric acid secretion is beyond the scope of this paper.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Blood glucose (a) and plasma insulin (b) concentrations during IV infusion of GLP-1, at 0.3 and 0.9 pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. *GLP-1 0.3 and 0.9 versus saline: P < .05; #GLP-1 0.9 versus GLP-1 0.3: P < .05 (adapted from Little et al. 2006 [19], and used with permission from the publisher).](https://figures.cochat.ai/paper-figures/12ab264a4ad24a26a6cba2d995beab18/effects-of-glp-1-and-incretin-based-therapies-on-gastrointestinal-motor-function-figure-1.jpg)
![Figure 2 Relationship between the area under the plasma glucose concentration curve between 0 and 30 minutes and the retention of the meal in the stomach at 30 minutes (r = 0.65, P < .01) (adapted from Horowitz et al. 1993 [45] and used with the permission of the publisher).](https://figures.cochat.ai/paper-figures/9c0d556b035e4aa9a9b1a00b73ec14a4/effects-of-glp-1-and-incretin-based-therapies-on-gastrointestinal-motor-function-figure-2.jpg)
![Figure 3 Gastric emptying curves for the solid and liquid components of a meal for the total, proximal, and distal stomach during IV infusion of GLP-1 at 0.3 and 0.9 pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. *GLP-1 0.3 and 0.9 versus saline: P < .05; #GLP-1 0.9 versus GLP-1 0.3: P < .05 (adapted from Little et al. 2006 [19] and used with permission from the publisher).](https://figures.cochat.ai/paper-figures/ce9fce815c1442429bc48b6a23974b19/effects-of-glp-1-and-incretin-based-therapies-on-gastrointestinal-motor-function-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RAs delay gastric emptying by inhibiting gastrointestinal motility through both PNS and CNS.”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, this promotes fundic relaxation, decreases peristalsis in the gastric antrum and duodenum, and increases pyloric sphincter tone, thereby delaying the transfer of gastric contents into the duodenum [29].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Constipation tended to last longer, and may be because of the effects of GLP‐1RAs on GI motility. 22”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
The mechanism of pancreatic secretion
Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,269
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995
Postprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945 · cited 1×
“Postprandial hyperglycaemia is being increasingly recognised as an independent predictor of cardiovascular mortality in both diabetic and nondiabetic populations [55, 56].”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“The insulinotropic property of GIP is markedly diminutesished in type 2 diabetic patients [89–91], probably in part as an effect of hyperglycaemia.”
Background
Research works printed but not linked: 16
- 1964, The Lancet, 284, 20
- 1997, American Journal of Physiology, 273, E981
- 2010, Neurogastroenterology & Motility, 22, article e1315, 1191
- 10.1210/jc.86.8.3853 · doi:10.1210/jc.86.8.3853 · Paper page
- 2004, Diabetes, Nutrition & Metabolism, 17, 336
- 1999, American Journal of Physiology, 277, G1217
- 1990, American Journal of Physiology, 259, G1031
- 1998, American Journal of Physiology, 275, R1293
- 1998, American Journal of Physiology, 275, R1308
- 1996, Journal of Nuclear Medicine, 37, 1643
- 1996, American Journal of Physiology, 271, G814
- 2002, American Journal of Physiology, 282, G424
- 2000, American Journal of Physiology, 278, G924
- 10.1210/jc.87.7.3078 · doi:10.1210/jc.87.7.3078
- 2010, Journal of Drug Design, Development and Therapy, 4, 279
- 2003, Diabetes, 52, A322
Cited by
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Microbial Modulation of Energy Availability in the Colon Regulates Intestinal Transit
Wichmann, A., Allahyar, A., Greiner, T. U., Plovier, H., Lundén, G. Ö., Larsson, T., Drucker, D. J., Delzenne, N. M., Cani, P. D., & Bäckhed, F. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.09.012 · Cited by 380
Kanasaki, K., Shi, S., Kanasaki, M., He, J., Nagai, T., Nakamura, Y., Ishigaki, Y., Kitada, M., Srivastava, S. P., & Koya, D. (2014) · Diabetes · doi:10.2337/db13-1029 · Cited by 359
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
Metadata
- Authors
- Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M.
- Affiliations
- Royal Adelaide Hospital (AU)
- Corresponding author
- Rayner, Christopher K.
- Venue
- Experimental Diabetes Research
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-10
- ISSN
- 1687-5214 (ISSN-L)
- 1687-5303
- PMC
- PMC3124003
- OpenAlex
- W2065444806
- Cited by
- 138
- References
- 111
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 20 · 2023: 3 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 10 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 9 · 2014: 6 · 2013: 12 · 2012: 1
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Experimental Diabetes Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, incretin-based therapy, gastrointestinal motility, enterogastrone, type 2 diabetes, anti-obesity, gastric emptying, gastric acid secretion
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Gastrointestinal Hormones, Gastrointestinal Motility, Humans, Movement, Peptides, Gastrointestinal Tract, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function. https://app.cochat.ai/papers/10.1155/2011/279530
- The paper
- Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011). Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function. Experimental Diabetes Research. https://doi.org/10.1155/2011/279530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.